PTC THERAPEUTICS, INC. PTCT revenue by segment, product and geography
In its fiscal year ending 2025-12-31, PTC THERAPEUTICS, INC. reported revenue across 10 products and services; the largest, Collaboration And License Revenue, was $998M (+328306.9% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Collaboration And License Revenue$998Mshare n/a+328306.9% yoy
- Product$587Mshare n/a+0.8% yoy
- Royalty$244Mshare n/a+19.8% yoy
- Translarna1$235Mshare n/a-26.7% yoy
- Emflaza$146Mshare n/a-29.4% yoy
- Sephience$111Mshare n/ano prior
- Translarna-$98.6Mshare n/a-624.5% yoy
- Upstaza And Kebilidi$56.6Mshare n/a+234.8% yoy
- +2 more members in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$252M30.7%+21.7% yoy
- Outside the United States$236M28.7%-40.1% yoy
- All Other Countries Other Than Russia Brazil And United States$168M20.5%-14.7% yoy
- RU$100M12.2%-4.7% yoy
- Brazil$65.7M8.0%-8.9% yoy
Members sum to $823M against $1.73B consolidated (residual $908M) - eliminations or corporate lines the filer did not tag on this axis.
- Product$239Mshare n/a+101.8% yoy
- Sephience$151Mshare n/ano prior
- Royalty$71.1Mshare n/a+23.4% yoy
- Collaboration And License Revenue$50.6Mshare n/a+1620.3% yoy
- Translarna$42.2Mshare n/a-29.0% yoy
- Emflaza$24.6Mshare n/a-32.2% yoy
- +2 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.